1. Home
  2. IGC vs FGL Comparison

IGC vs FGL Comparison

Compare IGC & FGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGC
  • FGL
  • Stock Information
  • Founded
  • IGC 2005
  • FGL 2021
  • Country
  • IGC United States
  • FGL Malaysia
  • Employees
  • IGC N/A
  • FGL N/A
  • Industry
  • IGC Biotechnology: Pharmaceutical Preparations
  • FGL
  • Sector
  • IGC Health Care
  • FGL
  • Exchange
  • IGC Nasdaq
  • FGL NYSE
  • Market Cap
  • IGC 29.4M
  • FGL 24.0M
  • IPO Year
  • IGC N/A
  • FGL 2024
  • Fundamental
  • Price
  • IGC $0.31
  • FGL $1.40
  • Analyst Decision
  • IGC Strong Buy
  • FGL
  • Analyst Count
  • IGC 2
  • FGL 0
  • Target Price
  • IGC $3.88
  • FGL N/A
  • AVG Volume (30 Days)
  • IGC 392.1K
  • FGL 104.4K
  • Earning Date
  • IGC 02-18-2025
  • FGL 12-17-2024
  • Dividend Yield
  • IGC N/A
  • FGL N/A
  • EPS Growth
  • IGC N/A
  • FGL 45.69
  • EPS
  • IGC N/A
  • FGL 0.04
  • Revenue
  • IGC $1,236,000.00
  • FGL $23,268,519.00
  • Revenue This Year
  • IGC N/A
  • FGL N/A
  • Revenue Next Year
  • IGC $18.34
  • FGL N/A
  • P/E Ratio
  • IGC N/A
  • FGL $36.30
  • Revenue Growth
  • IGC 1.64
  • FGL 336.06
  • 52 Week Low
  • IGC $0.26
  • FGL $1.25
  • 52 Week High
  • IGC $0.91
  • FGL $5.26
  • Technical
  • Relative Strength Index (RSI)
  • IGC 52.84
  • FGL N/A
  • Support Level
  • IGC $0.26
  • FGL N/A
  • Resistance Level
  • IGC $0.34
  • FGL N/A
  • Average True Range (ATR)
  • IGC 0.02
  • FGL 0.00
  • MACD
  • IGC 0.01
  • FGL 0.00
  • Stochastic Oscillator
  • IGC 65.88
  • FGL 0.00

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

About FGL FOUNDER GROUP LTD

Founder Group Ltd acts as an end-to-end Engineering, Procurement, Construction, and Commissioning solutions provider for solar PV facilities in Malaysia. The segments of the company are large-scale solar projects and commercial and industrial (C&I) solar projects. Large-scale solar projects of the company are utility-scale solar PV power plants with installed generating capacity of 1 MWac or more, and C&I projects of the company are smaller-scale solar projects where the solar PV systems are installed on rooftops and are designed to generate electricity for commercial and industrial properties for their consumption at factories, warehouses, and commercial stores. The company derives its revenue from Malaysia.

Share on Social Networks: